The Adolescent and Young Adult with Cancer: State of the Art - Epithelial Cancer

Current Oncology Reports

Volumn 15, Issue 4, 2013, Pages 287-295

  Ferreira, Carlos G ^a   De Melo, Andréia Cristina ^a   Nogueira Rodrigues, Angélica ^a  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

Adolescent; Epithelial cancer; Young adult

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; B RAF KINASE; BRCA1 PROTEIN; CISPLATIN; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; INTERFERON; IRINOTECAN; K RAS PROTEIN; MONOCLONAL ANTIBODY; OXALIPLATIN; PACLITAXEL; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PLATINUM COMPLEX; PROTEIN KINASE LKB1; TAMOXIFEN; VEMURAFENIB; WART VIRUS VACCINE;

ADOLESCENCE; ADULTHOOD; ARTICLE; BLADDER CARCINOMA; BRAF GENE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONDYLOMA ACUMINATUM; DOSE RESPONSE; DRUG MEGADOSE; DRUG SAFETY; EGFR GENE; EML4 ALK GENE; EPITHELIAL CANCER; EPITHELIUM TUMOR; GENE; GENE MUTATION; HER2 GENE; HUMAN; LKB1 GENE; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MELANOMA SKIN CANCER; METASTASIS; NASOPHARYNX CARCINOMA; ONCOGENE K RAS; ONCOGENE N RAS; OVERALL SURVIVAL; PAPILLOMAVIRUS INFECTION; PELVIS LYMPHADENECTOMY; PIK3CA GENE; PRACTICE GUIDELINE; RADICAL HYSTERECTOMY; THYROID CARCINOMA; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CANCER;

ADOLESCENT; ADULT; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; YOUNG ADULT;

EID: 84880775439     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-013-0322-8     Document Type: Article

References (83)

1. Closing the gap: research and care imperatives for adolescents and young adults with cancer report of the Adolescent and Young Adult Oncology Progress Review Group. http://planning.cancer.gov/library/AYAO-PRG-Report-2006-FINAL.pdf. Accessed February 2013.
2. Bleyer A. Young adult oncology: the patients and their survival challenges. CA Cancer J Clin. 2007;57:242-55. (Pubitemid 47312083)
3. Bleyer A, Viny A, Barr R. Cancer in 15- to 29-year-olds by primary site. Oncologist. 2006;11:590-601. (Pubitemid 43967614)
4. Bleyer A, O'Leary M, Barr R, Ries L, eds: Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival: 1975-2000. National Cancer Institute, NIH Pub. No. 06-5767. Bethesda, MD 2006.
5. Burke ME, Albritton K, Marina N. Challenges in the recruitment of adolescents and young adults to cancer clinical trials. Cancer. 2007;110:2385-93. (Pubitemid 350174923)
6. Ferrari A, Montello M, Budd T, Bleyer A. The challenges of clinical trials for adolescents and young adults with cancer. Pediatr Blood Cancer. 2008;50:1101-4. (Pubitemid 351500162)
7. Bleyer A, Budd T, Montello M. Adolescents and young adults with cancer: the scope of the problem and criticality of clinical trials. Cancer. 2006;107:1645-55. (Pubitemid 44537071)
8. Cinar P, Zell JA, Taylor TH, et al. Pediatric and AYA invasive cutaneous melanoma: population-based study comparing adult melanoma cases. J Clin Oncol (ASCO Meeting Abstracts). 2008;26:9071.
9. Armstrong BK, Kricker A, English DR. Sun exposure and skin cancer. Australas J Dermatol. 1997;38(Suppl):S1-6.
10. Krengel S, Hauschild A, Schafer T. Melanoma risk in congenital melanocytic naevi: a systematic review. Br J Dermatol. 2006;155:1-8. (Pubitemid 43876386)
11. Youl P, Aitken J, Hayward N, et al. Melanoma in adolescents: a case-control study of risk factors in Queensland, Australia. Int J Cancer. 2002;98:92-8. (Pubitemid 34113424)
12. Pappo AS. Melanoma in children and adolescents. Eur J Cancer. 2003;39:2651-61. (Pubitemid 37468306)
13. Hannah KW, Hauschild A, Loraine DM, et al. Melanoma in adolescents and young adults (ages 15-39 years): United States, 1999-2006. J Am Acad Dermatol. 2011 November;65(5 Suppl 1):S38-49.
14. Chao MM, Schwartz JL, Wechsler DS, et al. High-risk surgically resected pediatric melanoma and adjuvant interferon therapy. Pediatr Blood Cancer. 2005;44:441-8. (Pubitemid 40614491)
15. Navid F, Furman WL, Fleming M, et al. The feasibility of adjuvant interferon alpha-2b in children with high-risk melanoma. Cancer. 2005;103:780-7. (Pubitemid 40216407)
16. • Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 2011;29:1239-46. Recent advances in melanoma predictive biomarkers.
17. Daniotti M, Ferrari A, Frigerio S, et al. Cutaneous melanoma in childhood and adolescence shows frequent loss of INK4A and gain of KIT. J Invest Dermatol. 2009;129:1759-68.
18. • Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366:707-14. Recent advances in melanoma treatment.
19. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
20. Maggard MA, O'Connell JB, Lane KE, et al. Do young breast cancer patients have worse outcomes? J Surg Res. 2003;113:109-13. (Pubitemid 36999799)
21. Schairer C, Mink PJ, Carroll L, Devesa SS. Probabilities of death from breast cancer and other causes among female breast cancer patients. J Natl Cancer Inst. 2004;96:1311-21. (Pubitemid 39264120)
22. Xiong Q, Valero V, Kau V, et al. Female patients with breast carcinoma age 30 years and younger have a poor prog- nosis: the M.D. Anderson Cancer Center experience. Cancer. 2001;92:2523-8. (Pubitemid 33049434)
23. Ruddy KJ, Gelber S, Tamimi R, et al. Presentation of breast cancer in young women. J Clin Oncol. 2009;27:15s.
24. Colleoni M, Rotmensz N, Robertson C, et al. Very young women (< 35 years) with operable breast cancer: features of disease at presentation. Ann Oncol. 2002;13(2):273-9.
25. • Pronzato P, Mustacchi G, DeMatteis A, et al.: Biological Characteristics and Medical Treatment of Breast Cancer in Young Women - A Featured Population: Results from the NORA Study. Int J Breast Cancer 2011, article ID 534256, doi: 10.4061/2011/534256. Comprehensive biologic data of breast cancer in young women.
26. Freedman RA. Adjuvant therapies for very young women with early stage breast cancer. Breast. 2001;20:146-9.
27. •• Freedman RA, Virgo KS, Labadie J, et al. Receipt of locoregional therapy among young women with breast cancer. Breast Cancer Res Treat. 2012;135:893-906. Extensive data on locoregional treatment in AYA with breast cancer.
28. Arvold ND, Taghian AG, Niemierko A, et al. Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol. 2011;29:3885-91.
29. Kroman N, Jensen MB, Wohlfahrt J, et al. Factors influencing the effect of age on prognosis in breast cancer: population based study. British Medical Journal. 2000;320:474-8. (Pubitemid 30173116)
30. • Collaborative Group on Hormonal Factors in Breast Cancer: Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. The Lancet Oncology, Volume 13, Issue 11, Pages 1141-1151, November 2012. Meta-analysis of hormonal factors in breast cancer risk.
31. Davies C, Pan H, DPhil JG, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2012;381:805-16.
32. Cuschieri KS, Cubie HA, Whitley MW, et al. Multiple high risk HPV infections are common in cervical neoplasia and young women in a cervical screening population. J Clin Pathol. 2004;57:68-72. (Pubitemid 38091314)
33. Holowaty P, Miller AB, Rohan T, et al. Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst. 1999;91:252-8. (Pubitemid 29090994)
34. Zur Hausen H. Papillomavirus and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2:342-50. (Pubitemid 37328947)
35. Kawana K, Adachi K, Kojima S, Kozuma S, Fujii T. Therapeutic Human Papillomavirus (HPV) Vaccines: A Novel Approach. Open Virol J. 2012;6:264-9.
36. •• Kardakis S: Fertility-preserving surgery in patients with early stage cervical carcinoma. ISRN Oncol. 2012, In press. Review of fertility-preserving surgery in cervical carcinoma.
37. Morris M, Mitchell MF, Silva EG, Copeland LJ, Gershenson DM. Cervical conization as definitive therapy for early invasive squamous carcinoma of the cervix. Gynecol Oncol. 1993;51:193-6. (Pubitemid 24020363)
38. Wright JD, Nathavith Arana R, Lewin SN, et al. Fertility- conserving surgery for young women with stage IA1 cervical cancer: safety and access. Obstet Gynecol. 2010;115:585-90.
39. Arbyn M, Kyrgiou M, Simoens C, et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ. 2008;337:a1284.
40. Rob L, Charvat M, Robova H, et al. Less radical fertility-sparing surgery than radical trachelectomy in early cervical cancer. Int J Gynecol Cancer. 2007;17:304-10. (Pubitemid 46214010)
41. Milliken DA, Shepherd JH. Fertility preserving surgery for carcinoma of the cervix. Curr Opin Oncol. 2008;20:575-80.
42. Jolley JA, Battista L, Wing DA. Management of pregnancy after radical trachelectomy: case reports and systematic review of the literature. Am J Perinatol. 2007;24:531-9. (Pubitemid 47623683)
43. Boss EA, van Golde RJ, Beerendonk CC, Massuger LF. Pregnancy after radical trachelectomy: a real option? Gynecol Oncol. 2005;99 Suppl 1:S152-6. (Pubitemid 41774338)
44. Whitney CW, Sause W, Bundy BN, et al. A randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stages IIB- IVA carcinoma of the cervix with negative para-aortic lymph nodes: A Gynecology Oncology Group and Southwest Oncology Group Study. J Clin Oncology. 1999;17:1339-48. (Pubitemid 29220838)
45. Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy versus pelvic and para-aortic radiation for high-risk cervical cancer: A randomized Radiation Therapy Oncologic Group clinical trial. N Engl J Med. 1999;340:1137-43. (Pubitemid 29177872)
46. Peters III WA, Liu PY, Barret RJ, et al. Cisplatin and 5-fluorouracil plus radiation therapy are superior to radiation therapy as adjunctive in high-risk early stage carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: Report of a phase III intergroup study. J Clin Oncol. 2000;18:1606-13.
47. Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin based chemoradiation improves progression free and overall survival in an advanced cervical cancer: Results of a randomized Gynecologic Oncology Group Study. N Engl J Med. 1999;340:1144-53. (Pubitemid 29177873)
48. Keys HM, Bundy BM, Stehman FBV, et al. A comparison of weekly cisplatin during radiation therapy versus irradiation alone each followed by adjuvant hysterectomy in bulky stage IB cervical carcinoma: A randomized trial of the Gynecology Oncology Group. N Engl J Med. 1999;340:1154-61. (Pubitemid 29177874)
49. National Cancer Institute: NCI Clinical Announcement, Bethesda, MD, United States. Department of Health and Human Services, Public Health Service, National Institutes of Health, February 1999.
50. Pearcey R, Brundage M, Drouin P, et al. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol. 2002;20:966-72. (Pubitemid 34141839)
51. Tierney JF, Vale C, Symonds P. Concomitant and neoadjuvant chemotherapy for cervical cancer. Clin Oncol. 2008;20:401-16.
52. Dursun P, Ayhan A, Yanik FB, Kuşçu E. Ovarian transposition for the preservation of ovarian function in young patients with cervical carcinoma. Eur J Gynaecol Oncol. 2009;30:13-5.
53. Moore DH, Blessing JA, McQuellon RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 2004;22:3113-9. (Pubitemid 41103724)
54. Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet. 2005;365:2041-54. (Pubitemid 40812341)
55. • Buehrlen M, Zwaan CM, Granzen B, et al. Multimodal treatment, including interferon beta, of nasopharyngeal carcinoma in children and young adults: preliminary results from the prospective, multicenter study NPC-2003-GPOH/DCOG. Cancer. 2012;118(19):4892-900. Combined therapy was well tolerated and resulted in a very good outcome, superior to the outcomes of published results from all other pediatric NPC study groups.
56. Afqir S, Ismaili N, Alaoui K, et al. Nasopharyngeal carcinoma in adolescents: a retrospective review of 42 patients. Eur Arch Otorhinolaryngol. 2009;11:1767-73.
57. Ayan I, Kaytan E, Ayan N. Childhood nasopharyngeal carcinoma: from biology to treatment. Lancet Oncol. 2003;4:13-21. (Pubitemid 36124186)
58. Song CH, Wu HG, Heo DS, et al. Treatment outcomes for radiotherapy alone are comparable with neoadjuvant chemotherapy followed by radiotherapy in early-stage nasopharyngeal carcinoma. Laryngoscope. 2008;118:663-70. (Pubitemid 351496779)
59. Rodriguez-Galindo C, Wofford M, Castleberry RP, et al. Preradiation chemotherapy with methotrexate, cisplatin, 5-fluorouracil, and leucovorin for pediatric nasopharyngeal carcinoma. Cancer. 2005;103:850-7. (Pubitemid 40216415)
60. Ozyar E, Selek U, Laskar S, et al. Treatment results of 165 pediatric patients with non-metastatic nasopharyngeal carcinoma: a Rare Cancer Network study. Radiother Oncol. 2006;81:39-46. (Pubitemid 44512057)
61. Baujat B, Audry H, Bourhis J, et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys. 2006;64:47-56. (Pubitemid 41831208)
62. Caponigro F, Longo F, Ionna F, Perri F. Treatment approaches to nasopharyngeal carcinoma: a review. Anticancer Drugs. 2010;21:471-7.
63. Hung W, Sarlis NJ. Current controversies in the management of pediatric patients with well-differentiated nonmedullary thyroid cancer: a review. Thyroid. 2002;12:683-702. (Pubitemid 34913241)
64. • Rapkin L, Pashankar FD. Management of thyroid carcinoma in children and young adults. J Pediatr Hematol Oncol. 2012;34 Suppl 2:S39-46. Review of well differentiated thyroid cancer and medullary thyroid cancer.
65. DeLellis RA. Pathology and genetics of thyroid carcinoma. J Surg Oncol. 2006;94:662-9. (Pubitemid 44902064)
66. Grigsby PW, Gal-or A, Michalski JM, Doherty GM. Childhood and adolescent thyroid carcinoma. Cancer. 2002;95:724-9. (Pubitemid 34839662)
67. Niedziela M. Pathogenesis, diagnosis and management of thyroid nodules in children. Endocr Relat Cancer. 2006;13:427-53. (Pubitemid 43886667)
68. Stevens C, Lee JK, Sadatsafavi M, Blair GK. Pediatric thyroid fine-needle aspiration cytology: a meta-analysis. J Pediatr Surg. 2009;44:2184-91.
69. Rachmiel M, Charron M, Gupta A, et al. Evidence-based review of treatment and follow up of pediatric patients with differentiated thyroid carcinoma. J Pediatr Endocrinol Metab. 2006;19:1377-93. (Pubitemid 46043769)
70. Kiratli PO, Volkan-Salanci B, Günay EC, et al. Thyroid cancer in pediatric age group: an institutional experience and review of the literature. J Pediatr Hematol Oncol. 2013;35:93-7.
71. Tricoli JV, Seibel NL, Blair DG, et al. Unique characteristics of adolescent and young adult acute lymphoblastic leukemia, breast cancer, and colon cancer. J Natl Cancer Inst. 2011;103:628-35.
72. Pratt C. Management of infrequent tumors of childhood. In: Pizzo PA, Poplack DG, editors. Principles and Practice of Pediatric Oncology. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2002. p. 1149-76.
73. Compton C, Fenoglio-Preiser CM, Pettigrew N, et al. American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer. 2000;88:1739-57. (Pubitemid 30183160)
74. Blanke CD, Bot BM, Thomas DM, et al. Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials. J Clin Oncol. 2011;29(20):2781-6.
75. el-Mawla NG, el-Bolkainy MN, Khaled HM. Bladder cancer in Africa: update. Semin Oncol. 2001;28:174-8. (Pubitemid 32319391)
76. Defoor W, Minevich E, Sheldon C. Unusual bladder masses in children. Urology. 2002;60:911.
77. Paner GP, Zehnder P, Amin AM, et al. Urothelial neoplasms of the urinary bladder occurring in young adult and pediatric patients: a comprehensive review of literature with implications for patient management. Adv Anat Pathol. 2011;18:79-89.
78. Kreuzer M, Kreienbrock L, Gerken M, et al. Risk factors for lung cancer in young adults. Am J Epidemiol. 1998;147:1028-37.
79. Lal DR, Clark I, Shalkow J, et al. Primary epithelial lung malignancies in the pediatric population. Pediatr Blood Cancer. 2005;45:683-6. (Pubitemid 41279360)
80. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics 2010. CA Cancer J Clin. 2010;60:277-300.
81. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359:1367-80.
82. Pavlidis N. Lung cancer during pregnancy: an emerging issue. Lung Cancer. 2008 Mar;59:279-81. (Pubitemid 351335111)
83. SarIman N, Levent E, Yener NA, Orki A, SaygI A. Lung cancer and pregnancy. Lung Cancer. 2013;79:321-3.